D I S S E C T I N G B U S I N E S S
Clarivate, a leading global provider of transformative intelligence, released a new Companies to Watch report, Radioligand Innovators Ushering in a New Era of Precision Oncology. The report spotlights pioneering companies that are redefining the drug discovery and development landscape through advancements in radioligand therapies( RLTs) – a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity.
COMPANIES TO WATCH IN THE FUTURE OF PRECISION ONCOLOGY
Drawing on proprietary data, expert analysis and insights into therapeutic benefit, financing activity and R & D momentum, the report highlights why these organisations are considered highimpact innovators. This latest edition follows previous Companies to Watch reports focused on RNA-based technologies, Artificial Intelligence / Machine Learning( AI / ML), nextgeneration gene-editing and antibodydrug conjugates( ADCs).
Radioligand therapies represent one of the most promising frontiers in oncology, offering highly specific delivery of radioactive isotopes to tumour cells while minimising damage to healthy tissue. These agents are rapidly gaining momentum as both scientific breakthroughs and strategic investments accelerate across the global pharmaceutical landscape.
www. intelligenthealth. tech 29